B
BobH
ePharmaceuticals Cardio Topline by NewsEdge April 24, 2002
First Heart Valve Replacement Without Open Heart Surgery Experimental Device Developed By Percutaneous Valve Technologies May Provide Alternative to Open Heart Surgery In the United States
[PR Newswire]
FORT LEE, N.J., April 23 /PRNewswire/ via NewsEdge Corporation -- Percutaneous Valve Technologies, Inc. (PVT) -- a privately held medical technology company engaged in the development of a breakthrough device for the treatment of aortic stenosis -- announced today that its less invasive aortic valve procedure was performed in a cardiac catheterization laboratory, for the first time, avoiding open-heart surgery to treat senile aortic stenosis, a narrowing of the heart valve. This first clinical case was performed on April 16, 2002, by Dr. Alain Cribier, the chief of cardiology at the University of Rouen Hospital, Charles-Nicolle in Rouen, France. Next year clinical trials on this experimental device are expected to begin in the United States.
"The 57 year old male patient that received the aortic valve procedure, developed by Percutaneous Valve Technologies, had a failing heart and was refused for surgery by three surgical teams because of his deteriorating condition and complicated vascular disease," said Dr. Cribier. "Lacking any other clinical solution for this patient, the PVT valve was a life saving technology. We are pleased to be the world's first clinical site to utilize this breakthrough technology. This technology represents a new frontier in interventional cardiology."
The PVT device is a proprietary blend of balloon-expandable stent technology with a bioprosthetic valve made from biological tissue. The procedure deploys the stent across the old valve, holding it permanently open allowing for replacement of the old stenotic valve with a new one, thus removal of the failing valve is not required. This technology may be applicable to therapeutic conditions including the treatment of mitral stenosis, aortic regurgitation and venous insufficiency.
Dr. Cribier continues, "The patient's blood pressure returned to normal almost immediately, and his heart performance has improved dramatically. The PVT valve has proven many important principles today, including precise placement and anchoring, hemodynamic performance, and the acute improvement of heart function. This will be a very important option for non-surgical and high-risk patients with aortic stenosis. "
"Severe aortic stenosis is a disease that requires replacement of the valve in a highly invasive surgery," said Dr. Martin Leon, Lenox Hill Hospital in New York, NY. "The ability to perform this procedure in a cath lab as demonstrated in this first patient is a historic event in cardiology, ranking with the first stent implantation in a human almost 20 years ago."
"This case was the world's first human implant of an aortic heart valve in the cardiac cath lab," said Stanton Rowe, president and chief executive officer, Percutaneous Valve Technologies. "There are many patients with aortic stenosis who are not good candidates for surgery who could benefit from this less invasive option. Many of these patients are debilitated with no options but intensive medical therapy, which fails to improve their heart function."
Aortic stenosis is a narrowing of the heart valve that causes the heart to work very hard to eject blood into the body. It results in shortness of breath, and in advanced cases, may result in fainting and heart failure. Symptomatic patients are typically treated by surgery.
Over 300,000 patients every year have surgery on their heart valves. Sixty percent of valve replacement surgeries are for the aortic valve. Aortic stenosis occurs predominantly in an elderly population, many over 70 years of age. These patients are at higher risk of surgical complications and many have other complicating illnesses.
For more information about PVT, visit their Web site at www.pvtechnologies.com <http://www.pvtechnologies.com>.
About PVT
Percutaneous Valve Technologies, Inc. (PVT) located in Fort Lee, NJ, with a subsidiary in Israel, is a privately held medical technology company developing an innovative, percutaneous approach for delivering heart valves to treat late-stage aortic stenosis. This less invasive device, designed by PVT, is a proprietary blend of balloon-expandable stent technology with a bioprosthetic valve made from biological tissue. The procedure deploys the stent across the old valve, holding it permanently open allowing for replacement of the old stenotic valve with a new one, thus removal of the failing valve is not required. It is designed to be delivered in a cardiac catheterization laboratory under local anesthesia, using fluoroscopic guidance, thereby avoiding general anesthesia and highly invasive open-heart surgery techniques currently used in valve replacement.
CONTACT:
Stanton Rowe
President & CEO
Percutaneous Valve Technologies, Inc.
201-363-8901
[email protected] <mailto:[email protected]>
MAKE YOUR OPINION COUNT - Click Here
<http://tbutton.prnewswire.com/prn/11690X60574898>
SOURCE Percutaneous Valve Technologies, Inc. (PVT)
/CONTACT: Stanton Rowe, President & CEO of Percutaneous Valve Technologies, Inc., +1-201-363-8901, [email protected]/ <mailto:[email protected]/> /Web site: <http://www.pvtechnologies.com/>
<< Copyright ©2002 PR Newswire >>
This is a news service of NewsEdge Corporation <http://www.newsedge.com/iviews.htm> c2000. This content is for your personal use only, subject to Terms and Conditions. No redistribution allowed.
First Heart Valve Replacement Without Open Heart Surgery Experimental Device Developed By Percutaneous Valve Technologies May Provide Alternative to Open Heart Surgery In the United States
[PR Newswire]
FORT LEE, N.J., April 23 /PRNewswire/ via NewsEdge Corporation -- Percutaneous Valve Technologies, Inc. (PVT) -- a privately held medical technology company engaged in the development of a breakthrough device for the treatment of aortic stenosis -- announced today that its less invasive aortic valve procedure was performed in a cardiac catheterization laboratory, for the first time, avoiding open-heart surgery to treat senile aortic stenosis, a narrowing of the heart valve. This first clinical case was performed on April 16, 2002, by Dr. Alain Cribier, the chief of cardiology at the University of Rouen Hospital, Charles-Nicolle in Rouen, France. Next year clinical trials on this experimental device are expected to begin in the United States.
"The 57 year old male patient that received the aortic valve procedure, developed by Percutaneous Valve Technologies, had a failing heart and was refused for surgery by three surgical teams because of his deteriorating condition and complicated vascular disease," said Dr. Cribier. "Lacking any other clinical solution for this patient, the PVT valve was a life saving technology. We are pleased to be the world's first clinical site to utilize this breakthrough technology. This technology represents a new frontier in interventional cardiology."
The PVT device is a proprietary blend of balloon-expandable stent technology with a bioprosthetic valve made from biological tissue. The procedure deploys the stent across the old valve, holding it permanently open allowing for replacement of the old stenotic valve with a new one, thus removal of the failing valve is not required. This technology may be applicable to therapeutic conditions including the treatment of mitral stenosis, aortic regurgitation and venous insufficiency.
Dr. Cribier continues, "The patient's blood pressure returned to normal almost immediately, and his heart performance has improved dramatically. The PVT valve has proven many important principles today, including precise placement and anchoring, hemodynamic performance, and the acute improvement of heart function. This will be a very important option for non-surgical and high-risk patients with aortic stenosis. "
"Severe aortic stenosis is a disease that requires replacement of the valve in a highly invasive surgery," said Dr. Martin Leon, Lenox Hill Hospital in New York, NY. "The ability to perform this procedure in a cath lab as demonstrated in this first patient is a historic event in cardiology, ranking with the first stent implantation in a human almost 20 years ago."
"This case was the world's first human implant of an aortic heart valve in the cardiac cath lab," said Stanton Rowe, president and chief executive officer, Percutaneous Valve Technologies. "There are many patients with aortic stenosis who are not good candidates for surgery who could benefit from this less invasive option. Many of these patients are debilitated with no options but intensive medical therapy, which fails to improve their heart function."
Aortic stenosis is a narrowing of the heart valve that causes the heart to work very hard to eject blood into the body. It results in shortness of breath, and in advanced cases, may result in fainting and heart failure. Symptomatic patients are typically treated by surgery.
Over 300,000 patients every year have surgery on their heart valves. Sixty percent of valve replacement surgeries are for the aortic valve. Aortic stenosis occurs predominantly in an elderly population, many over 70 years of age. These patients are at higher risk of surgical complications and many have other complicating illnesses.
For more information about PVT, visit their Web site at www.pvtechnologies.com <http://www.pvtechnologies.com>.
About PVT
Percutaneous Valve Technologies, Inc. (PVT) located in Fort Lee, NJ, with a subsidiary in Israel, is a privately held medical technology company developing an innovative, percutaneous approach for delivering heart valves to treat late-stage aortic stenosis. This less invasive device, designed by PVT, is a proprietary blend of balloon-expandable stent technology with a bioprosthetic valve made from biological tissue. The procedure deploys the stent across the old valve, holding it permanently open allowing for replacement of the old stenotic valve with a new one, thus removal of the failing valve is not required. It is designed to be delivered in a cardiac catheterization laboratory under local anesthesia, using fluoroscopic guidance, thereby avoiding general anesthesia and highly invasive open-heart surgery techniques currently used in valve replacement.
CONTACT:
Stanton Rowe
President & CEO
Percutaneous Valve Technologies, Inc.
201-363-8901
[email protected] <mailto:[email protected]>
MAKE YOUR OPINION COUNT - Click Here
<http://tbutton.prnewswire.com/prn/11690X60574898>
SOURCE Percutaneous Valve Technologies, Inc. (PVT)
/CONTACT: Stanton Rowe, President & CEO of Percutaneous Valve Technologies, Inc., +1-201-363-8901, [email protected]/ <mailto:[email protected]/> /Web site: <http://www.pvtechnologies.com/>
<< Copyright ©2002 PR Newswire >>
This is a news service of NewsEdge Corporation <http://www.newsedge.com/iviews.htm> c2000. This content is for your personal use only, subject to Terms and Conditions. No redistribution allowed.
